Artificial intelligence has come to optical design. Rayner’s RayOne Galaxy, designed with the help of AI, is being touted as a continuous full-range-of-vision IOL and will feature a world-first spiral optical design completely free of diffractive elements.
Rayner (Worthing, United Kingdom) announced today that it will unveil its RayOne Galaxy continuous full-range-of-vision spiral intraocular lens (IOL) at the upcoming 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2024) in Barcelona.
Launching 75 years after Rayner and Sir Harold Ridley released the first-ever IOL in 1949, RayOne Galaxy’s spiral optics were developed with renowned Brazilian surgeon Dr. João Lyra and refined using artificial intelligence analysis of patient outcomes. The lens will be fully preloaded and immediately available in toric powers.
“We all read about the life changing potential of AI, but this is a real-world example of technology impacting the outcomes of patients,” said Rayner CEO Tim Clover in a statement.
“RayOne Galaxy represents a next-generation technology in intraocular lenses to enable patients to see without spectacles. Launching the world’s first spiral optic lens on the 75th anniversary of the world’s first IOL feels poetic and I’m proud that Rayner is still at the forefront of technology, partnering with innovative surgeons from all over the world and making a difference to the life of millions of patients every year.”
Rayner is keeping exact details on the spiral design itself close to the chest prior to the lens’ debut in Barcelona. However, the company has claimed that the lens will be non-diffractive, provide continuous full range of vision, minimize dysphotopsia—all with 0% light loss.
As for what surgeons can expect from the significant innovations, Mr. Allon Barsam, Consultant Ophthalmic Surgeon and Director at acclaimed London clinic OCL Vision and an investigator with firsthand experience of RayOne Galaxy, gave a sneak peek of early returns on the lens’ performance.
“The first patients received RayOne Galaxy at OCL Vision in July and their feedback so far has been overwhelmingly positive, with patients reading without glasses and thrilled with their quality of vision,” he said.
Clinical investigations on the lens commenced earlier this year, and outcomes will be reported at an upcoming ESCRS 2024 Rayner symposium on September 7. Until then, the cataract world will have to wait for what the product of two of the most exciting innovations in ophthalmology has in store.